Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$6.51
-0.8%
$6.24
$4.47
$35.98
$7.16M0.9399,915 shs34,939 shs
Nuvilex Inc. stock logo
PMCB
Nuvilex
$1.10
-3.4%
$1.08
$1.00
$2.42
$7.55M-0.4219,633 shs4,487 shs
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
$1.54
-7.0%
$1.45
$1.17
$7.60
$7M1.44600,798 shs292,844 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%-0.08%-0.91%+27.80%-65.98%
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.00%+6.89%+7.94%-3.42%-47.32%
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
0.00%+4.78%+1.66%+3.02%+347.52%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollomics Inc. stock logo
APLM
Apollomics
0.334 of 5 stars
0.05.00.00.00.60.00.0
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.8922 of 5 stars
0.03.00.00.00.60.81.9
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
3.1139 of 5 stars
3.55.00.00.02.30.80.6
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollomics Inc. stock logo
APLM
Apollomics
0.00
N/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
0.00
N/AN/AN/A
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
3.00
Buy$15.00877.20% Upside
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollomics Inc. stock logo
APLM
Apollomics
$1.49M4.80N/AN/A$4.48 per share1.45
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/A$3.27 per shareN/A
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
$34.87M0.20N/AN/A$9.10 per share0.17
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollomics Inc. stock logo
APLM
Apollomics
-$53.86MN/A0.00N/AN/AN/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
$330K$0.741.49N/AN/A0.51%0.35%8/11/2025 (Estimated)
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
-$5.13M-$150.88N/AN/A-13.88%-21.25%-16.89%8/15/2025 (Estimated)
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A

Latest VBIV, APLM, SBFM, and PMCB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
N/A-$0.44N/A-$0.44N/A$8.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/AN/AN/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/AN/AN/AN/AN/A
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollomics Inc. stock logo
APLM
Apollomics
N/A
1.39
1.39
Nuvilex Inc. stock logo
PMCB
Nuvilex
N/A
14.21
14.21
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
N/A
4.25
2.19
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21

Institutional Ownership

CompanyInstitutional Ownership
Apollomics Inc. stock logo
APLM
Apollomics
19.13%
Nuvilex Inc. stock logo
PMCB
Nuvilex
34.24%
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
41.98%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%

Insider Ownership

CompanyInsider Ownership
Apollomics Inc. stock logo
APLM
Apollomics
N/A
Nuvilex Inc. stock logo
PMCB
Nuvilex
10.20%
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
0.10%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollomics Inc. stock logo
APLM
Apollomics
451.10 millionN/ANot Optionable
Nuvilex Inc. stock logo
PMCB
Nuvilex
46.86 million6.16 millionOptionable
Sunshine Biopharma, Inc. stock logo
SBFM
Sunshine Biopharma
34.56 million4.55 millionNot Optionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable

Recent News About These Companies

VBI recalls PreHevbrio and winds down operations
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI craters as investors react to Hep B vaccine data
VBI Vaccines Reports Full Year 2023 Financial Results

Media Sentiment Over Time

Apollomics stock logo

Apollomics NASDAQ:APLM

$6.50 -0.06 (-0.84%)
Closing price 07/3/2025 02:27 PM Eastern
Extended Trading
$6.10 -0.40 (-6.15%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Nuvilex stock logo

Nuvilex NASDAQ:PMCB

$1.10 -0.04 (-3.42%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Sunshine Biopharma stock logo

Sunshine Biopharma NASDAQ:SBFM

$1.54 -0.12 (-6.97%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.51 -0.03 (-1.89%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.